ES2174573T3 - Procedimientos de identificacion de substancias para la inhibicion de las lesiones neoplasticas. - Google Patents
Procedimientos de identificacion de substancias para la inhibicion de las lesiones neoplasticas.Info
- Publication number
- ES2174573T3 ES2174573T3 ES99308129T ES99308129T ES2174573T3 ES 2174573 T3 ES2174573 T3 ES 2174573T3 ES 99308129 T ES99308129 T ES 99308129T ES 99308129 T ES99308129 T ES 99308129T ES 2174573 T3 ES2174573 T3 ES 2174573T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- activity
- determining
- pde
- cox
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Se da a conocer una composición farmacéutica para el tratamiento de la neoplasia, que comprende un portador farmacéuticamente aceptable y un compuesto seleccionado por: determinación de la actividad inhibitoria de la ciclooxigenasa (COX) del compuesto; determinación de la actividad de inhibición del PDE del compuesto en el que el PDE se caracteriza por: (a) especificidad del cGMP sobre cAMP; (b) comportamiento cinético cooperativo en presencia de sustrato de cGMP; (c) afinidad submicromolecular por cGMP; y (d) insensibilidad a la incubación con quinasa de proteína dependiente de cGMP; y selección del compuesto que tiene actividad inhibitoria de COX inferior que dicha actividad de PDE para tratamiento de la neoplasia. La invención también provee un procedimiento para seleccionar el tratamiento de la neoplasia, que comprende determinación de la actividad inhibitoria de la ciclooxigenasa (COX) del compuesto; determinación de la actividad inhibitoria de PDE2 del compuesto; y selección del compuesto con actividad inhibitoria del COX inferior para el tratamiento de la neoplasia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/173,375 US6200771B1 (en) | 1998-10-15 | 1998-10-15 | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
US09/366,003 US6130053A (en) | 1999-08-03 | 1999-08-03 | Method for selecting compounds for inhibition of neoplastic lesions |
US09/414,628 US20020009764A1 (en) | 1999-10-08 | 1999-10-08 | Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2174573T3 true ES2174573T3 (es) | 2002-11-01 |
Family
ID=27390268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES99308129T Expired - Lifetime ES2174573T3 (es) | 1998-10-15 | 1999-10-14 | Procedimientos de identificacion de substancias para la inhibicion de las lesiones neoplasticas. |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP0997145B1 (es) |
JP (1) | JP2000186047A (es) |
CN (1) | CN100389829C (es) |
AT (1) | ATE214920T1 (es) |
AU (1) | AU770308B2 (es) |
CA (1) | CA2284853A1 (es) |
DE (1) | DE69901082T2 (es) |
DK (1) | DK0997145T3 (es) |
ES (1) | ES2174573T3 (es) |
IL (1) | IL132366A0 (es) |
NO (2) | NO994995L (es) |
TR (1) | TR199902578A3 (es) |
TW (1) | TWI239837B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002531826A (ja) * | 1998-11-25 | 2002-09-24 | セル パスウェイズ インコーポレイテッド | 新形成診断法 |
US6569638B1 (en) * | 2000-03-03 | 2003-05-27 | Cell Pathways, Inc | Method for screening compounds for the treatment of neoplasia |
CZ2003486A3 (cs) * | 2000-08-21 | 2003-05-14 | Astrazeneca Ab | Chinazolinové deriváty, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
WO2004044234A1 (en) * | 2002-11-13 | 2004-05-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a) |
JP4641942B2 (ja) | 2003-10-03 | 2011-03-02 | フェーイレン・ナムローゼ・フェンノートシャップ | ヒトおよび動物におけるigf−1血清レベルの低下と関連した種々の疾患状態の治療用の治療用組成物の製造のための血清中igf−1レベルを増加できる化合物の使用 |
WO2005054181A1 (ja) * | 2003-12-01 | 2005-06-16 | Reverse Proteomics Research Institute Co., Ltd. | 抗癌剤の新規標的タンパク質および対応する新規抗癌剤(スプナール) |
JP5219135B2 (ja) * | 2008-07-25 | 2013-06-26 | 独立行政法人産業技術総合研究所 | 炎症性疾患モデル動物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0508586B1 (en) * | 1991-03-08 | 1995-05-31 | Fgn, Inc. | Substituted indenyl compounds |
US5696159A (en) * | 1994-08-03 | 1997-12-09 | Cell Pathways, Inc. | Lactone compounds for treating patients with precancerous lesions |
US5776962A (en) * | 1994-08-03 | 1998-07-07 | Cell Pathways, Inc. | Lactone compounds for treating patient with precancerous lesions |
US5998477A (en) * | 1996-06-13 | 1999-12-07 | Cell Pathways Inc. | Substituted methoxy benzylidene indenyl-acetic and propionic acids for treating patients with precancerous lesions |
US6063818A (en) * | 1996-06-13 | 2000-05-16 | Cell Pathways Inc. | Substituted benzylidene indenyl formamides, acetamides and propionamides |
AU740783B2 (en) * | 1996-09-18 | 2001-11-15 | Applied Genetics Incorporated Dermatics | Pharmaceutical compositions and methods |
CA2238283C (en) * | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
US5922595A (en) * | 1997-12-09 | 1999-07-13 | Incyte Pharmaceuticals, Inc. | Cyclic GMP phosphodiesterase |
JP4307719B2 (ja) * | 1997-12-12 | 2009-08-05 | セル パスウェイズ インコーポレイテッド | 新形成治療用のn−ベンジル−3−インデニルアセトアミド誘導体 |
-
1999
- 1999-10-13 IL IL13236699A patent/IL132366A0/xx not_active IP Right Cessation
- 1999-10-14 CA CA002284853A patent/CA2284853A1/en not_active Abandoned
- 1999-10-14 DE DE69901082T patent/DE69901082T2/de not_active Expired - Fee Related
- 1999-10-14 EP EP99308129A patent/EP0997145B1/en not_active Expired - Lifetime
- 1999-10-14 AU AU54010/99A patent/AU770308B2/en not_active Ceased
- 1999-10-14 TW TW088117817A patent/TWI239837B/zh active
- 1999-10-14 EP EP01119687A patent/EP1161943A3/en not_active Withdrawn
- 1999-10-14 AT AT99308129T patent/ATE214920T1/de not_active IP Right Cessation
- 1999-10-14 ES ES99308129T patent/ES2174573T3/es not_active Expired - Lifetime
- 1999-10-14 DK DK99308129T patent/DK0997145T3/da active
- 1999-10-14 NO NO994995A patent/NO994995L/no not_active Application Discontinuation
- 1999-10-15 JP JP11330364A patent/JP2000186047A/ja active Pending
- 1999-10-15 CN CNB991218183A patent/CN100389829C/zh not_active Expired - Fee Related
- 1999-10-15 TR TR1999/02578A patent/TR199902578A3/tr unknown
-
2006
- 2006-06-09 NO NO20062682A patent/NO20062682L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2284853A1 (en) | 2000-04-15 |
DK0997145T3 (da) | 2002-07-29 |
JP2000186047A (ja) | 2000-07-04 |
CN100389829C (zh) | 2008-05-28 |
TWI239837B (en) | 2005-09-21 |
CN1255379A (zh) | 2000-06-07 |
NO994995D0 (no) | 1999-10-14 |
AU770308B2 (en) | 2004-02-19 |
EP1161943A3 (en) | 2003-12-10 |
DE69901082T2 (de) | 2002-08-29 |
NO994995L (no) | 2000-04-17 |
IL132366A0 (en) | 2001-03-19 |
EP0997145B1 (en) | 2002-03-27 |
TR199902578A2 (xx) | 2000-06-21 |
NO20062682L (no) | 2000-04-17 |
ATE214920T1 (de) | 2002-04-15 |
EP1161943A2 (en) | 2001-12-12 |
AU5401099A (en) | 2000-04-20 |
DE69901082D1 (de) | 2002-05-02 |
TR199902578A3 (tr) | 2000-06-21 |
EP0997145A1 (en) | 2000-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0316502A (pt) | Compostos quìmicos | |
NO941937D0 (no) | Sakarinderivater som inhiberer proteolytiske enzymer | |
ES2164717T3 (es) | Compuestos triciclicos de sulfonamida utiles para inhibir la funcion de la proteina-g y para el tratamiento de enfermedades proliferativas. | |
BR0013966A (pt) | Compostos espiroeterocìclicos úteis como inibidores reversìveis de proteases de cisteìna | |
FI925787A0 (fi) | Proteolytiska enzymers sackarinderivatinhibitorer | |
BR0012243A (pt) | Triflúor butenos nematocidas | |
EA200200208A1 (ru) | Синергитическая композиция | |
BG105112A (en) | Agents with antidepressive effect | |
CO4790154A1 (es) | Compuestos heterociclicos como inhibidores de enzimas rota- masas | |
NO20062682L (no) | Farmasoytiske blandinger inneholdende forbindelser for inhibering av neoplastiske lesjoner | |
ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
GT199900154A (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. | |
ATE326964T1 (de) | Aminosäurederivate zur behandlung der alzheimer- krankheit | |
ES2167678T3 (es) | Tratamiento y profilaxis de la pancreatitis. | |
ATE289204T1 (de) | Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie | |
BR0009101A (pt) | 9a-azalidas com atividade antibacteriana | |
ATE267194T1 (de) | Medikamente geeignet zur behandlung von proliferativen erkrankungen | |
AR024963A1 (es) | Oxazincarbazoles en el tratamiento de enfermedades del snc | |
ES2144857T3 (es) | Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso. | |
ES2168240T3 (es) | Uso de inhibidores de aceticolina-esterasa para tratar delirios. | |
BR9711960A (pt) | Verapamil como um medicamento para o tratamento de angina | |
DE50012667D1 (de) | Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen | |
ATE286728T1 (de) | Verwendung von homocysteinderivaten zur behandlung von bakteriellen infektionen | |
DE60034580D1 (de) | Peptid zur behandlung von nervenerkrankungen | |
ES2179668T3 (es) | Un compuesto wf002, su produccion y su uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 997145 Country of ref document: ES |